SCHEMBL14707520

SCHEMBL14707520

C[C@H](CCl)COc1ccc(C(C)(C)c2ccc(OC[C@H](O)CO)cc2)cc1

nearest known ligand 0.82

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ AR P10275 6/20 0.82
▸ HTT P42858 2/20 0.58
▸ HIF1A Q16665 1/20 0.58
▸ KMT2A Q03164 3/20 0.46
▸ KDM4E B2RXH2 3/20 0.43
▸ MAPT P10636 2/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ GAA P10253 1/20 0.43
▸ MAPK1 P28482 2/20 0.41
▸ TSHR P16473 1/20 0.41
▸ MEN1 O00255 2/20 0.41
▸ NPC1 O15118 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ VDR P11473 6/20 0.39
▸ LMNA P02545 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ MITF O75030 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14707519 1.00 AR (0.82) ARHTTHIF1AKMT2AKDM4E
SCHEMBL13826212 1.00 AR (0.82) ARHTTHIF1AKMT2AKDM4E
SCHEMBL12267221 1.00 AR (0.82) ARHTTHIF1AKMT2AKDM4E
SCHEMBL14707518 1.00 AR (0.82) ARHTTHIF1AKMT2AKDM4E
SCHEMBL14707517 1.00 AR (0.82) ARHTTHIF1AKMT2AKDM4E
SCHEMBL12267198 0.92 AR (0.76) ARHTTHIF1AKMT2AKDM4E
SCHEMBL12267194 0.90 AR (1.00) ARHTTHIF1AKMT2AKDM4E
SCHEMBL12267202 0.90 AR (0.74) ARHTTHIF1AKMT2AKDM4E
SCHEMBL15257224 0.90 AR (1.00) ARHTTHIF1AKMT2AKDM4E
SCHEMBL13736034 0.90 AR (1.00) ARHTTHIF1AKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11814357-B2 Solid forms of an N-terminal domain androgen receptor inhibitor and uses thereof ESSA PHARMA INC. (CA) 2023-11-14 — — US disclosed
US-20170056336-A1 CO-TARGETING ANDROGEN RECEPTOR SPLICE VARIANTS AND MTOR SIGNALING PATHWAY FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2017-03-02 — — US disclosed
US-20160068466-A1 ESTER DERIVATIVES OF ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2016-03-10 — — US disclosed
US-9173939-B2 Ester derivatives of androgen receptor modulators and methods for their use THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2015-11-03 — — US disclosed
US-20140335080-A1 ESTER DERIVATIVES OF ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2014-11-13 — — US disclosed
US-20130245129-A1 DIGLYCIDIC ETHER DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2013-09-19 — — US disclosed
US-20130045204-A1 FLUORINATED BISPHENOL ETHER COMPOUNDS AND METHODS FOR THEIR USE THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2013-02-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130045204-A1 FLUORINATED BISPHENOL ETHER COMPOUNDS AND METHODS FOR THEIR USE AR, ESRRA, ESR1 AR 1/4885HTT 3985/4885HIF1A 3869/4885
US-20130245129-A1 DIGLYCIDIC ETHER DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE MAN2B2, UGCG, KLK3 AR 179/4885HTT 4659/4885HIF1A 1235/4885
US-11814357-B2 Solid forms of an N-terminal domain androgen receptor inhibitor and uses thereof AR, NR5A1, SHBG AR 1/4885HTT 3733/4885HIF1A 3775/4885
US-20160068466-A1 ESTER DERIVATIVES OF ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE AR, ESRRA, KLK3 AR 1/4885HTT 3604/4885HIF1A 4638/4885
US-20140335080-A1 ESTER DERIVATIVES OF ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE AR, ESRRA, KLK3 AR 1/4885HTT 3604/4885HIF1A 4638/4885
US-20170056336-A1 CO-TARGETING ANDROGEN RECEPTOR SPLICE VARIANTS AND MTOR SIGNALING PATHWAY FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER AR, MTOR, RICTOR AR 1/4885HTT 2567/4885HIF1A 1770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback